FDA Approves Ivosidenib as First-Line Treatment for AML with IDH1 Mutation

It is approved in patients who are at least 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy
06 May 2019
Haematologic malignancies;  Cancer in Special Situations / Population;  Personalised medicine;  Anticancer agents & Biologic therapy

On 2 May 2019, the US Food and Drug Administration (FDA) approved ivosidenib (TIBSOVO, Agios Pharmaceuticals, Inc.) for newly-diagnosed acute myeloid leukaemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, in patients who are at least 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy.

Approval was based on an open-label, single-arm, multicentre clinical trial (Study AG120-C-001, NCT02074839) of single-agent ivosidenib for newly-diagnosed AML with an IDH1 mutation detected by the Abbott RealTimeTM IDH1 Assay.

Patients enrolled were at least 75 years old or met at least one of the following criteria: baseline Eastern Cooperative Oncology Group performance status of ≥ 2, severe cardiac or pulmonary disease, hepatic impairment with bilirubin > 1.5 times the upper limit of normal, or creatinine clearance < 45 mL/min. The 28 patients treated had a median age of 77 years (range, 64-87 years), and 22 (79%) had therapy-related AML or AML with myelodysplasia-related changes. Ivosidenib was administered orally at a dose of 500 mg daily until disease progression, development of unacceptable toxicity, or haematopoietic stem cell transplantation. Two of the 28 patients underwent stem cell transplantation following ivosidenib.

Efficacy was based on the rate of complete remission (CR) or complete remission with partial haematologic recovery (CRh), the duration of CR+CRh, and the conversion rate from transfusion dependence to transfusion independence. Twelve (42.9%) of the 28 achieved CR+CRh (95% CI: 24.5, 62.8), and 7 (41.2%) of the 17 transfusion-dependent patients achieved transfusion independence lasting at least 8 weeks.

The adverse reactions that occurred in at least 25% of patients were diarrhoea, fatigue, oedema, decreased appetite, leukocytosis, nausea, arthralgia, abdominal pain, dyspnoea, differentiation syndrome and myalgia. Prescribing information contains a Boxed Warning alerting healthcare professionals and patients about the risk of differentiation syndrome which may be life-threatening or fatal.

The recommended ivosidenib dose is 500 mg orally once daily with or without food until disease progression or unacceptable toxicity. For patients without disease progression or unacceptable toxicity, treatment is recommended for a minimum of 6 months to allow time for clinical response.

Full prescribing information for TIBSOVO is available here.

This application used the Real-Time Oncology Review pilot programme. FDA granted this application priority review and orphan product designation.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

Last update: 06 May 2019

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings